{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T11:56:52Z","timestamp":1792151812340,"version":"4.4.0"},"reference-count":50,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T00:00:00Z","timestamp":1652659200000},"content-version":"unspecified","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2022,2,21]]},"published-print":{"date-parts":[[2022,5]]},"abstract":"\n Objective<\/jats:title>\n Tofacitinib is an oral Janus kinase for the treatment of rheumatoid arthritis (RA). This post hoc analysis assessed whether baseline body mass index (BMI) impacts tofacitinib efficacy in patients with RA.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Pooled data from six phase 3 studies in patients receiving tofacitinib 5\u2009mg (N=1589) or 10\u2009mg (N=1611) twice daily or placebo (advancing to active treatment at months 3 or 6; N=680), \u00b1conventional synthetic disease-modifying antirheumatic drugs, were stratified by baseline BMI (<25, 25 to <30, \u226530\u2009kg\/m2<\/jats:sup>). Endpoints (through to month 6) were assessed descriptively: American College of Rheumatology 20\/50\/70 response rates; changes from baseline (\u2206) in Disease Activity Score in 28 joints, erythrocyte sedimentation rate (DAS28-4(ESR)), DAS28-4(C-reactive protein), Clinical Disease Activity Index (CDAI), Health Assessment Questionnaire-Disability Index (HAQ-DI) and pain; and proportions of patients achieving DAS28-4(ESR) \u22651.2\u2009and HAQ-DI \u22650.22 decreases from baseline, low disease activity (DAS28-4(ESR) \u22643.2\u2009or CDAI \u226410) and radiographic non-progression (\u0394modified Total Sharp Score \u22640.5; months 12 and 24). Estimates were adjusted using multivariable models for selected outcomes. Univariate\/multivariable regression analyses determined predictors of month 6 outcomes.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Of 3880 patients included, 1690 (43.6%), 1173 (30.2%) and 1017 (26.2%) had baseline BMI <25, 25 to <30 and \u226530\u2009kg\/m2<\/jats:sup>, respectively. Tofacitinib showed greater efficacy improvements versus placebo in each BMI category. Differences in efficacy outcomes (adjusted and unadjusted) were generally not clinically meaningful across BMI categories within treatment groups. In regression analyses, BMI was not consistently associated with selected outcomes.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Baseline BMI did not consistently affect tofacitinib response suggesting that tofacitinib is an effective oral treatment option for adults with moderate to severe RA regardless of baseline BMI, including patients with BMI \u226530\u2009kg\/m2<\/jats:sup>.<\/jats:p>\n <\/jats:sec>\n \n Trial registration numbers<\/jats:title>\n \n NCT00814307<\/jats:ext-link>, NCT01039688<\/jats:ext-link>; NCT00960440<\/jats:ext-link>; NCT00847613<\/jats:ext-link>; NCT00856544<\/jats:ext-link>; NCT00853385<\/jats:ext-link>.<\/jats:p>\n <\/jats:sec>","DOI":"10.1136\/rmdopen-2021-002103","type":"journal-article","created":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T13:34:24Z","timestamp":1653312864000},"page":"e002103","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":29,"title":["Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by baseline body mass index: an analysis of pooled data from phase 3 studies"],"prefix":"10.1136","volume":"8","clinical-trial-number":[{"clinical-trial-number":"nct00814307","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01039688","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00960440","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00847613","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00856544","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00853385","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2010-3272","authenticated-orcid":false,"given":"Ara H","family":"Dikranian","sequence":"first","affiliation":[{"name":"Cabrillo Center for Rheumatic Disease, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7924-7406","authenticated-orcid":false,"given":"Miguel A","family":"Gonzalez-Gay","sequence":"additional","affiliation":[{"name":"Section of Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Wellborne","sequence":"additional","affiliation":[{"name":"Rheumatic Innovative Therapies, Houston Institute for Clinical Research, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Mar\u00eda","family":"\u00c1lvaro-Gracia","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liza","family":"Takiya","sequence":"additional","affiliation":[{"name":"Inflammation and Immunology, Pfizer Inc, Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Stockert","sequence":"additional","affiliation":[{"name":"Inflammation and Immunology, Pfizer Inc, Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Paulissen","sequence":"additional","affiliation":[{"name":"Inflammation and Immunology, Pfizer Inc, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Shi","sequence":"additional","affiliation":[{"name":"Inflammation and Immunology, Pfizer Inc, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svitlana","family":"Tatulych","sequence":"additional","affiliation":[{"name":"Inflammation and Immunology, Pfizer Inc, Groton, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8907-8976","authenticated-orcid":false,"given":"Jeffrey R","family":"Curtis","sequence":"additional","affiliation":[{"name":"Division of Clinical Immunology and Rheumatology, The University of Alabama at Birmingham, Birmingham, Alabama, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,5,16]]},"reference":[{"key":"2025090312540726000_8.1.e002103.1","doi-asserted-by":"publisher","DOI":"10.1002\/art.33383"},{"key":"2025090312540726000_8.1.e002103.2","doi-asserted-by":"publisher","DOI":"10.1002\/art.33419"},{"key":"2025090312540726000_8.1.e002103.3","doi-asserted-by":"publisher","DOI":"10.1002\/art.24567"},{"key":"2025090312540726000_8.1.e002103.4","doi-asserted-by":"publisher","DOI":"10.3109\/14397595.2014.995875"},{"key":"2025090312540726000_8.1.e002103.5","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/acr.20494","article-title":"Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate","volume":"63","author":"Tanaka","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090312540726000_8.1.e002103.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61424-X"},{"key":"2025090312540726000_8.1.e002103.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1109071"},{"key":"2025090312540726000_8.1.e002103.8","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-159-4-201308200-00006"},{"key":"2025090312540726000_8.1.e002103.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310476"},{"key":"2025090312540726000_8.1.e002103.10","doi-asserted-by":"publisher","DOI":"10.1002\/art.37816"},{"key":"2025090312540726000_8.1.e002103.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112072"},{"key":"2025090312540726000_8.1.e002103.12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31618-5"},{"key":"2025090312540726000_8.1.e002103.13","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"2025090312540726000_8.1.e002103.14","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.130683"},{"key":"2025090312540726000_8.1.e002103.15","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13075-016-0932-2","article-title":"Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study","volume":"18","author":"Yamanaka","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2025090312540726000_8.1.e002103.16","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13075-019-1866-2","article-title":"Safety and efficacy of tofacitinib for up to 9.5\u2009years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study","volume":"21","author":"Wollenhaupt","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2025090312540726000_8.1.e002103.17","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s13075-020-02194-z","article-title":"Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies","volume":"22","author":"Genovese","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"2025090312540726000_8.1.e002103.18","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1002\/acr.21978","article-title":"Association of high body mass index with decreased treatment response to combination therapy in recent-onset rheumatoid arthritis patients","volume":"65","author":"Heimans","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090312540726000_8.1.e002103.19","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/acr.21768","article-title":"Obesity and reduction of the response rate to anti-tumor necrosis factor \u03b1 in rheumatoid arthritis: an approach to a personalized medicine","volume":"65","author":"Gremese","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090312540726000_8.1.e002103.20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195123","article-title":"Obesity and response to anti-tumor necrosis factor-\u03b1 agents in patients with select immune-mediated inflammatory diseases: a systematic review and meta-analysis","volume":"13","author":"Singh","year":"2018","journal-title":"PLoS One"},{"key":"2025090312540726000_8.1.e002103.21","first-page":"4","article-title":"Recent advances in the relationship between obesity, inflammation, and insulin resistance","volume":"17","author":"Bastard","year":"2006","journal-title":"Eur Cytokine Netw"},{"key":"2025090312540726000_8.1.e002103.22","first-page":"712","article-title":"Obesity, adipose tissue and rheumatoid arthritis: coincidence or more complex relationship?","volume":"29","author":"Derdemezis","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"2025090312540726000_8.1.e002103.23","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205544"},{"key":"2025090312540726000_8.1.e002103.24","doi-asserted-by":"publisher","DOI":"10.1002\/art.24789"},{"key":"2025090312540726000_8.1.e002103.25","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-018-1575-2","article-title":"Smoking, body mass index, disease activity, and the risk of rapid radiographic progression in patients with early rheumatoid arthritis","volume":"20","author":"Rydell","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2025090312540726000_8.1.e002103.26","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker294"},{"key":"2025090312540726000_8.1.e002103.27","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-017-1412-z","article-title":"A somatization comorbidity phenotype impacts response to therapy in rheumatoid arthritis: post-hoc results from the certolizumab pegol phase 4 PREDICT trial","volume":"19","author":"Curtis","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"2025090312540726000_8.1.e002103.28","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1177\/009286151104500409","article-title":"Covariate-adjusted difference in proportions from clinical trials using logistic regression and weighted risk differences","volume":"45","author":"Ge","year":"2011","journal-title":"Drug Inf J"},{"key":"2025090312540726000_8.1.e002103.29","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-9868.2005.00503.x"},{"key":"2025090312540726000_8.1.e002103.30","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-205079"},{"key":"2025090312540726000_8.1.e002103.31","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1002\/acr.22606","article-title":"Determining the minimally important difference in the clinical disease activity index for improvement and worsening in early rheumatoid arthritis patients","volume":"67","author":"Curtis","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090312540726000_8.1.e002103.32","first-page":"557","article-title":"Minimum important difference between patients with rheumatoid arthritis: the patient's perspective","volume":"20","author":"Wells","year":"1993","journal-title":"J Rheumatol"},{"key":"2025090312540726000_8.1.e002103.33","doi-asserted-by":"publisher","DOI":"10.1002\/art.37711"},{"key":"2025090312540726000_8.1.e002103.34","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s13075-019-1909-8","article-title":"Outcome of patients with early arthritis without rheumatoid factor and ACPA and predictors of rheumatoid arthritis in the ESPOIR cohort","volume":"21","author":"Mouterde","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2025090312540726000_8.1.e002103.35","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1007\/s00296-015-3271-8","article-title":"Associations of rheumatoid factor and anti-citrullinated peptide antibody with disease progression and treatment outcomes in patients with rheumatoid arthritis","volume":"35","author":"Katchamart","year":"2015","journal-title":"Rheumatol Int"},{"key":"2025090312540726000_8.1.e002103.36","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s13075-016-1146-3","article-title":"Body mass index and extent of MRI-detected inflammation: opposite effects in rheumatoid arthritis versus other arthritides and asymptomatic persons","volume":"18","author":"Mangnus","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2025090312540726000_8.1.e002103.37","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2016-eular.4363","article-title":"SAT0058\u2005Consistency of radiographic responses with sarilumab plus methotrexate across subpopulations of patients with rheumatoid arthritis in a phase 3 study [abstract]","volume":"75","author":"van der Heijde","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2025090312540726000_8.1.e002103.38","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-75673-7","article-title":"Association between obesity and remission in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs","volume":"10","author":"Abuhelwa","year":"2020","journal-title":"Sci Rep"},{"key":"2025090312540726000_8.1.e002103.39","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001203"},{"key":"2025090312540726000_8.1.e002103.40","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1080\/19420862.2016.1216741","article-title":"The underlying inflammatory chronic disease influences infliximab pharmacokinetics","volume":"8","author":"Passot","year":"2016","journal-title":"MAbs"},{"key":"2025090312540726000_8.1.e002103.41","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.491"},{"key":"2025090312540726000_8.1.e002103.42","doi-asserted-by":"publisher","DOI":"10.1186\/2047-783x-15-s2-120"},{"key":"2025090312540726000_8.1.e002103.43","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.jbspin.2015.02.011","article-title":"Body mass index and response to rituximab in rheumatoid arthritis","volume":"82","author":"Ottaviani","year":"2015","journal-title":"Joint Bone Spine"},{"key":"2025090312540726000_8.1.e002103.44","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1007\/s10067-017-3788-1","article-title":"Body mass index and clinical response to intravenous or subcutaneous abatacept in patients with rheumatoid arthritis","volume":"36","author":"D'Agostino","year":"2017","journal-title":"Clin Rheumatol"},{"key":"2025090312540726000_8.1.e002103.45","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.140673"},{"key":"2025090312540726000_8.1.e002103.46","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1093\/rheumatology\/kez535","article-title":"Obesity reduces the real-world effectiveness of cytokine-targeted but not cell-targeted disease-modifying agents in rheumatoid arthritis","volume":"59","author":"Sch\u00e4fer","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2025090312540726000_8.1.e002103.47","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001486"},{"key":"2025090312540726000_8.1.e002103.48","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/apt.16439","article-title":"The impact of body mass index on efficacy and safety in the tofacitinib OCTAVE ulcerative colitis clinical programme","volume":"54","author":"Farraye","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"2025090312540726000_8.1.e002103.49","doi-asserted-by":"crossref","DOI":"10.3390\/metabo10030107","article-title":"The interrelations between biological and targeted synthetic agents used in inflammatory joint diseases, and obesity or body composition","volume":"10","author":"Toussirot","year":"2020","journal-title":"Metabolites"},{"key":"2025090312540726000_8.1.e002103.50","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-020-02297-7","article-title":"Increased high molecular weight adiponectin and lean mass during tocilizumab treatment in patients with rheumatoid arthritis: a 12-month multicentre study","volume":"22","author":"Toussirot","year":"2020","journal-title":"Arthritis Res Ther"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2021-002103","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:54:16Z","timestamp":1756929256000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2021-002103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,5,16]]},"published-print":{"date-parts":[[2022,5]]}},"alternative-id":["10.1136\/rmdopen-2021-002103"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2021-002103","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5]]}}}